S 4189: INSULIN Act of 2026

S 4189 in plain English: The INSULIN Act of 2026 would cap out-of-pocket costs for insulin at $35 per month's supply for individuals covered under applicable health plans. Starting in 2028, the cap would be the lesser of $35 or 25 percent of the negotiated price. The bill also authorizes funding to support implementation.

Stated purpose

The bill aims to reduce the price of insulin for patients and create protections against high out-of-pocket costs, including for people without insurance.

Key points

• Caps insulin out-of-pocket costs at $35 per 1-month supply for plan years before January 1, 2028
• Beginning January 1, 2028, caps insulin costs at the lesser of $35 or 25% of the negotiated price
• Authorizes $100,000,000 for fiscal year 2027 to carry out the program
• Authorizes $2,000,000 per year for fiscal years 2027 through 2032 for a related provision

Arguments supporters make

• Insulin is a life-sustaining medication, and capping costs at $35 a month ensures people with diabetes can afford it without skipping doses or rationing.
• Requiring PBMs to pass rebates through to plans increases transparency and could lower the actual cost insurers pay, reducing pressure on premiums over time.
• The bill has bipartisan support, showing that protecting patients from extreme insulin prices is a broadly shared goal across party lines.

Arguments opponents make

• Capping what patients pay does not lower the underlying list price of insulin, so the true cost is simply shifted to insurers and ultimately spread across all policyholders through higher premiums.
• The bill's cost to the federal government is not offset in the bill itself — Congress only expresses a vague intention to address that later, leaving the fiscal impact unresolved.
• Mandating coverage terms for private insurance expands federal control over health plans, which critics argue should be left to markets or states to determine.

Tradeoffs

Capping patient out-of-pocket costs for insulin provides immediate relief to people who use it, but may shift costs to insurers and other policyholders or leave the federal fiscal impact unaddressed; stronger short-term patient protections are weighed against questions about who ultimately bears the expense.

Current status in Congress: In committee.

NewsClear — neutral news & congressional tracking · Bill of the Week